Nature Communications (Nov 2021)
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
Abstract
Triple negative breast cancer can be divided into additional subtypes. Here, using omics analyses, the authors show that in the mesenchymal subtype expression of MHC-1 is repressed and that this can be restored by using drugs that target subunits of the epigenetic modifier PRC2.